STAAR Surgical Management
Management criteria checks 2/4
STAAR Surgical's CEO is Tom Frinzi, appointed in Jan 2023, has a tenure of 4.58 years. total yearly compensation is $10.22M, comprised of 7.7% salary and 92.3% bonuses, including company stock and options. directly owns 0.046% of the company’s shares, worth €541.95K. The average tenure of the management team and the board of directors is 2 years and 3.3 years respectively.
Key information
Tom Frinzi
Chief executive officer
US$10.2m
Total compensation
| CEO salary percentage | 7.7% |
| CEO tenure | 2yrs |
| CEO ownership | 0.05% |
| Management average tenure | 2yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 27 2024 | n/a | n/a | US$22m |
| Jun 28 2024 | n/a | n/a | US$17m |
| Mar 29 2024 | n/a | n/a | US$15m |
| Dec 29 2023 | US$10m | US$788k | US$21m |
| Sep 29 2023 | n/a | n/a | US$20m |
| Jun 30 2023 | n/a | n/a | US$26m |
| Mar 31 2023 | n/a | n/a | US$33m |
| Dec 30 2022 | US$274k | n/a | US$40m |
| Sep 30 2022 | n/a | n/a | US$38m |
| Jul 01 2022 | n/a | n/a | US$34m |
| Apr 01 2022 | n/a | n/a | US$29m |
| Dec 31 2021 | US$250k | n/a | US$28m |
| Oct 01 2021 | n/a | n/a | US$23m |
| Jul 02 2021 | n/a | n/a | US$21m |
| Apr 02 2021 | n/a | n/a | US$11m |
| Jan 01 2021 | US$182k | n/a | US$6m |
Compensation vs Market: Tom's total compensation ($USD10.22M) is above average for companies of similar size in the German market ($USD1.57M).
Compensation vs Earnings: Tom's compensation has increased by more than 20% in the past year.
CEO
Tom Frinzi (68 yo)
2yrs
Tenure
US$10,220,581
Compensation
Mr. Thomas G. Frinzi, also known as Tom, serves as Executive Chairman of the Board at ViaLase, Inc. since November 2022 and joined the company in November 2022. He serves as Executive Chair at Aurion Biote...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2yrs | US$10.22m | 0.046% € 542.0k | |
| Chief Financial Officer | 4.5yrs | US$2.82m | 0.070% € 816.2k | |
| Chief Operating Officer | 1.8yrs | US$3.42m | 0.0089% € 103.8k | |
| Chief Technology Officer | 7.8yrs | US$2.41m | 0.036% € 423.2k | |
| Chief Medical Officer | 7.3yrs | US$2.48m | 0.064% € 746.3k | |
| Vice President of Investor Relations & Corporate Development | no data | no data | no data | |
| Senior VP | 1.1yrs | no data | no data | |
| Chief Marketing Officer | less than a year | no data | no data | |
| Senior Vice President of Commercial Operations - North America & APAC | 8.2yrs | US$2.54m | 0.060% € 706.2k | |
| Chief Clinical | 1.8yrs | no data | 0.0061% € 71.7k | |
| Senior Vice President of Operations | no data | no data | no data |
2.0yrs
Average Tenure
60.5yo
Average Age
Experienced Management: SR3's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.6yrs | US$10.22m | 0.046% € 542.0k | |
| Lead Independent Director | 9yrs | US$294.87k | 0.031% € 360.9k | |
| Independent Director | 2.6yrs | US$259.96k | 0.031% € 365.6k | |
| Independent Director | 1.1yrs | US$99.69k | 0.0093% € 108.9k | |
| Member of Optometric Advisory Council | 16.2yrs | no data | no data | |
| Independent Director | less than a year | no data | 0.0085% € 100.2k | |
| Independent Director | less than a year | no data | 0.0072% € 84.3k | |
| Independent Director | 4yrs | US$249.99k | 0.010% € 121.4k |
3.3yrs
Average Tenure
55yo
Average Age
Experienced Board: SR3's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 04:20 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/27 |
| Annual Earnings | 2023/12/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
STAAR Surgical Company is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joanne Wuensch | BMO Capital Markets U.S. (Historical) |
| Michael Gorman | BTIG |
| John Young | Canaccord Genuity |